CI
CRBP icon

Conning Inc’s Corbus Pharmaceuticals CRBP Stock Holding History

Conning Inc’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-11,709
Closed -$2.38M – 580
2016
Q3 		$2.38M Buy
+11,709
New +$1.46M 0.1% 160

Other funds holding CRBP

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
RJFSA
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Conning Inc's CRBP Position: Q4 2016 in Review

Conning Inc sold out of Corbus Pharmaceuticals (CRBP) in Q4 2016, closing a stake of 11,709 shares — an estimated $2.38M sold.

Conning Inc first reported a position in CRBP in Q3 2016 and held it in 1 quarter. The position peaked at $2.38M in Q3 2016. 49 funds tracked by Wall St. Rank hold CRBP as of Q4 2016.

  • Conning Inc reported no remaining Corbus Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Conning Inc sold 11,709 Corbus Pharmaceuticals shares in Q4 2016, an estimated $2.38M.
  • Conning Inc first reported a position in Corbus Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Conning Inc's Corbus Pharmaceuticals position peaked at $2.38M in Q3 2016.
  • 49 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2016.

Based on Conning Inc's 13F filing for Q4 2016, filed 2 Feb 2017.